The Pharmacokinetics and Safety Characteristics of Docetaxel in Patients With Cancer

This study has been completed.
Information provided by:
Hospira, Inc. Identifier:
First received: October 8, 2010
Last updated: December 28, 2010
Last verified: December 2010

The purpose of this study is to compare the pharmacokinetic and safety characteristics of Taxotere® with Hospira docetaxel in patients with cancer.

Condition Intervention Phase
Cancer for Which Taxanes Are a Suitable Treatment Option.
Drug: European Taxotere
Drug: American Taxotere
Drug: Hospira Docetaxel Injection
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase I Double-blinded, Randomized Three-period, Three-treatment, Crossover Study to Compare the Intravenous Pharmacokinetic and Safety Characteristics of European Taxotere® and American Taxotere® With Hospira Docetaxel Injection Administered at a Therapeutic Dose in Cancer Patients.

Resource links provided by NLM:

Further study details as provided by Hospira, Inc.:

Primary Outcome Measures:
  • AUC (0-tlast); Cmax [ Time Frame: Day -21 through Day 57 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • T(1/2); Plasma Clearance, Vss [ Time Frame: Day -21 through Day 57 ] [ Designated as safety issue: Yes ]

Enrollment: 26
Study Start Date: June 2007
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
European Taxotere (Taxotere EU) 60-100 mg/m2
Drug: European Taxotere
60 mg/m2 IV
Experimental: 3
Hospira Docetaxel Injection 60-100 mg/m2
Drug: Hospira Docetaxel Injection
60-100 mg/m2 IV
Active Comparator: 2
American Taxotere (Taxotere US) 60-100 mg/m2
Drug: American Taxotere
60-100 mg/m2 IV

Detailed Description:

No information is available on the pharmacokinetic characteristics, safety or efficacy of Hospira Docetaxel Injection. The primary purpose of this study therefore is to compare the pharmacokinetic characteristics of 60-100 mg/m² Hospira Docetaxel Injection, 60-100 mg/m² European Taxotere® (Taxotere® EU) and 60-100 mg/m² American Taxotere® (Taxotere® US) when administered as a 1 hour intravenous infusion in man. The secondary objective of this study will be to compare the safety and tolerability of Hospira Docetaxel Injection, Taxotere® EU and Taxotere® US. The study will also provide an opportunity to assess selected efficacy endpoints according to local practice after each cycle of treatment.

The study dosing regimen (60-100 mg/m², administered as a 1 hour intravenous infusion at 3 week intervals) and subject population (cancer patients for whom Taxotere® monotherapy would be a suitable treatment option) were selected on the basis of the licensed use of 60-100 mg/m² Taxotere®. The randomised crossover design was chosen to reduce the effect of intersubject variation.

Since Hospira Docetaxel Injection has not been administered to man there is no information on the risks associated with its clinical use. However the active ingredient of Hospira Docetaxel Injection is the same as that of Taxotere® and it is expected that Hospira Docetaxel Injection will exhibit a similar safety and tolerability profile.

An estimated 24 patients will be recruited at several UK sites and one Russian site to provide 19 evaluable patients


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent
  • Medically documented cancer for which Taxotere® monotherapy is a suitable treatment option
  • ECOG performance status 0 - 1
  • Haematological and serum chemical parameters in accordance with the protocol
  • Effective method of contraception as specified in the protocol
  • Willing and able to comply with the protocol

Exclusion Criteria:

  • Concomitant treatment with any other cytotoxic agent
  • Concomitant use of compounds that induce, inhibit or are metabolized by cytochrome P450
  • History or presence of any clinically in the opinion of the Investigator, would preclude inclusion in the study
  • Clinically significant vital signs or 12-lead ECG results
  • Participation in any other clinical trial using an investigational drug within the previous month
  • History of Hepatitis B Virus, Hepatitis C Virus or Human Immunodeficiency Virus
  • Recent or clinically significant history of drug or alcohol abuse
  • Insulin-dependent or unstable Diabetes Mellitus
  • History of severe hypersensitivity reactions to Taxotere® or to other drugs formulated with Polysorbate 80
  • History of reaction to any drug containing polyethylene glycol 300 (PEG 300);
  • Pregnancy or lactation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01268163

Russian Federation
N.N. Petrov Research Institute of Oncology
St. Petersburg, Russian Federation
United Kingdom
Christie Hospital, Manchester
Glasgow,, Cambridge, United Kingdom
Sponsors and Collaborators
Hospira, Inc.
Principal Investigator: M. Ranson Christie Hospital, Manchester
Principal Investigator: V Semiglazov N.N. Petrov Research Institute of Oncology
  More Information

No publications provided

Responsible Party: Rodeina Challand, Hospira, Inc. Identifier: NCT01268163     History of Changes
Other Study ID Numbers: DOE061
Study First Received: October 8, 2010
Last Updated: December 28, 2010
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
Russia: Ministry of Health of the Russian Federation

Keywords provided by Hospira, Inc.:
Phase I

Additional relevant MeSH terms:
Antimitotic Agents
Antineoplastic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators processed this record on July 05, 2015